171 related articles for article (PubMed ID: 15054447)
1. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
Morant R; Bernhard J; Dietrich D; Gillessen S; Bonomo M; Borner M; Bauer J; Cerny T; Rochlitz C; Wernli M; Gschwend A; Hanselmann S; Hering F; Schmid HP
Br J Cancer; 2004 Apr; 90(7):1312-7. PubMed ID: 15054447
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
3. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study.
Morant R; Hsu Schmitz SF; Bernhard J; Thürlimann B; Borner M; Wernli M; Egli F; Forrer P; Streit A; Jacky E; Hanselmann S; Bauer J; Hering F; Schmid HP
Eur J Cancer; 2002 Aug; 38(12):1626-32. PubMed ID: 12142053
[TBL] [Abstract][Full Text] [Related]
5. Synchronous chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck using capecitabine: a single-centre, open-label, single-group phase II study.
Jegannathen A; Mais K; Sykes A; Lee L; Yap B; Birzgalis A; Homer J; Ryder WD; Slevin N
Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):149-58. PubMed ID: 20951012
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
[TBL] [Abstract][Full Text] [Related]
7. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).
Morant R; Bernhard J; Maibach R; Borner M; Fey MF; Thürlimann B; Jacky E; Trinkler F; Bauer J; Zulian G; Hanselmann S; Hürny C; Hering F
Ann Oncol; 2000 Feb; 11(2):183-8. PubMed ID: 10761753
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Blum JL; Dieras V; Lo Russo PM; Horton J; Rutman O; Buzdar A; Osterwalder B
Cancer; 2001 Oct; 92(7):1759-68. PubMed ID: 11745247
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
[TBL] [Abstract][Full Text] [Related]
10. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Vaishampayan UN; Marur S; Heilbrun LK; Cher ML; Dickow B; Smith DW; Al Hasan SA; Eliason J
J Urol; 2009 Jul; 182(1):317-23. PubMed ID: 19447430
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Hoff PM; Pazdur R; Lassere Y; Carter S; Samid D; Polito D; Abbruzzese JL
J Clin Oncol; 2004 Jun; 22(11):2078-83. PubMed ID: 15169794
[TBL] [Abstract][Full Text] [Related]
13. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Wagstaff AJ; Ibbotson T; Goa KL
Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
Kolodziej M; Neubauer MA; Rousey SR; Pluenneke RE; Perrine G; Mull S; Boehm KA; Ilegbodu D; Asmar L
Clin Genitourin Cancer; 2006 Sep; 5(2):155-61. PubMed ID: 17026805
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Wolf JK; Bodurka DC; Verschraegen C; Sun CC; Branham D; Jenkins AD; Atkinson N; Gershenson DM
Gynecol Oncol; 2006 Sep; 102(3):468-74. PubMed ID: 16516276
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
Pagliaro LC; Perez CA; Tu SM; Daliani DD
Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.
Cartwright TH; Cohn A; Varkey JA; Chen YM; Szatrowski TP; Cox JV; Schulz JJ
J Clin Oncol; 2002 Jan; 20(1):160-4. PubMed ID: 11773165
[TBL] [Abstract][Full Text] [Related]
19. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Bajetta E; Di Bartolomeo M; Mariani L; Cassata A; Artale S; Frustaci S; Pinotti G; Bonetti A; Carreca I; Biasco G; Bonaglia L; Marini G; Iannelli A; Cortinovis D; Ferrario E; Beretta E; Lambiase A; Buzzoni R;
Cancer; 2004 Jan; 100(2):279-87. PubMed ID: 14716761
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.
Pisano C; Morabito A; Sorio R; Breda E; Lauria R; Gebbia V; Scaltriti L; Scalone S; Zagonel V; Greggi S; Beneduce G; Losito S; Gallo C; Di Maio M; Forestieri V; Pignata S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1021-7. PubMed ID: 19266200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]